4. Regulatory Overhaul for Plasma-Derived Medicinal Products (PDMPs)

• Streamlining Blood Product Testing: The Ministry of Health and Family Welfare has proposed a draft notification (March 9, 2026) to amend the Drugs Rules, 1945. The primary change is the elimination of \'double testing\' for viral markers (HIV, Hepatitis B, and Hepatitis C) at the finished product stage. • Shift to Global Standards: India is aligning its protocols with international benchmarks such as the British, United States, and European Pharmacopoeias. These standards prioritize testing the \'first homogeneous pool\' of raw plasma rather than repeating identical tests on the final medicine. • Reducing Production Costs and Delays: Currently, India imports over 60% of its plasma-derived products. Removing redundant final-stage testing is expected to reduce administrative and financial burdens on manufacturers, accelerating the supply of life-saving treatments.  • Critical Therapies in Focus: The reform targets essential medicines like Albumin (for trauma/burn patients), Immunoglobulins (for immune disorders), and Clotting Factors (for Hemophilia), making them more affordable and accessible. • Emphasis on Source Safety: The new framework shifts the safety burden to the \'collection level.\' This necessitates strengthening pan-India donor screening, ensuring Nucleic Acid Testing (NAT) for all donors, and maintaining 100% traceability of plasma units. • Economic Impact: By rationalizing manufacturing, the government aims to bolster a domestic market valued at approximately $383.5 million (2024), fostering \'Atmanirbharta\' (self-reliance) in the highgrowth pharmaceutical bioproducts sector. Key Definitions • Plasma-Derived Medicinal Products (PDMPs): Medicines manufactured from human plasma (the liquid component of blood), used to treat rare, chronic, and life-threatening conditions. • Nucleic Acid Testing (NAT): A highly sensitive blood screening technology that detects the genetic material of viruses (like HIV) much earlier than traditional antibody tests, reducing the \'window period\' of infection. • Pharmacopoeia: An official publication containing a list of medicinal drugs with their effects and directions for their use, serving as a quality standard for the industry. Constitutional and Legal Provisions • Article 47 (DPSP): Directs the State to regard the improvement of public health as among its primary duties. Rationalizing drug rules to improve availability of life-saving medicines aligns with this mandate. • Drugs and Cosmetics Act, 1940: The parent legislation that regulates the import, manufacture, distribution, and sale of drugs in India. • Drugs Rules, 1945: Subordinate legislation providing the specific procedures for drug testing and licensing. The proposed amendment specifically targets these rules to modernize blood-related protocols. • Entry 19, List I (Union List): Gives the Central Government exclusive power over \'Medicines and Drugs,\' allowing the Ministry of Health to set uniform national standards for blood products. Additional Key Points for Examination • The \'Window Period\' Challenge: While double testing is being removed, the efficacy of this move depends entirely on the sensitivity of initial donor screening to catch infections that haven\'t yet produced antibodies. • Viral Inactivation: Expert opinion highlights that the manufacturing process itself involves multiple viral inactivation steps (like heat treatment or solvent-detergent steps), making finished product testing largely redundant if source material is clean. • Import Dependency: High reliance on imports makes India vulnerable to global supply chain shocks; domestic regulatory easing is a strategic move for health security. Conclusion The proposed amendment to the Drugs Rules, 1945, represents a pragmatic shift from \'procedural redundancy\' to \'scientific efficiency.\' By focusing on the quality of raw plasma and aligning with global pharmacopoeial standards, India aims to lower the cost of biological therapies. However, the success of this transition rests on the stringent implementation of NAT testing and robust traceability at every blood bank across the country to maintain public trust in the safety of plasma-derived medicines. UPSC Relevance • GS Paper II: Governance and Public Health; Government policies and interventions for development in various sectors; Issues relating to the development and management of Social Sector/Health. • GS Paper III: Science and Technology-developments and their applications and effects in everyday life; indigenization of technology; Bio-technology and Pharma industry. • Prelims: Components of blood (Plasma vs. Serum), NAT testing, functions of the Central Drugs Standard Control Organization (CDSCO), and the significance of the Indian Pharmacopoeia.